2000 SIERRA POINT PARKWAY, BRISBANE, CA
Reports First Quarter 2026 Financial Results and Provides Business Update
Developing Advanced Therapies for Cancer Patients
Financial Results, Press Release
News, Securities Holder Rights or Indentures, Material Contracts
Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
Investor Presentation
Tempest Therapeutics Acquires CAR T-Cell Therapy Assets from Erigen LLC
Material disclosure
Q1
FY 2025
Q3
Q2
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Notice of Exempt Offering of Securities
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Schedule 13D - Ownership Report
Initial Statement of Beneficial Ownership
S-8 POS
Correspondence
Submission Upload